Leadership Team

Murray Stewart, DM FRCP, is a Senior Medical Advisor to several companies and is also a board director with X4 pharmaceuticals and Camp4. Previously he was the corporate Chief Medical Officer at GlaxoSmithKline and subsequently the Chief Medical Officer and/or head of R&D at Rhythm Pharmaceuticals and Novelion Therapeutics, Inc.

Dr. Stewart has extensive clinical development experience in designing and completing studies through all stages of development from first time in human studies to large phase 4 cardiovascular outcome studies. He also provides guidance and strategy for early compounds in development in both small molecules and biologics as well as submissions of files in the US, EU, and the rest of the world, including Asia and Japan with several successful registrations and launches of compounds, including Avandia, Arixtra, Albiglutide, and Ambrisentan.

Before joining the pharmaceutical industry, Dr. Stewart worked as a diabetes consultant and senior lecturer and was Consultant Physician/Honorary Senior Lecturer and Head of Clinical Services at the Diabetes Centre, Newcastle upon Tyne in the UK. His research was in lipid metabolism in type 2 diabetes, and he completed his medical training at Southampton Medical School in the UK and is a Fellow of the Royal College of Physicians.